Semaglutide (Rybelsus)
Keyword(s):
Clinical evidence suggests that Rybelsus should be reimbursed to treat type 2 diabetes in adults if it is used in addition to metformin or other antihyperglycemic agents and does not cost more than glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors. Rybelsus is more costly than most similar diabetes treatments. Rybelsus is expected to increase budgets by more than $38 million over 3 years. To account for the high treatment cost, the price of Rybelsus should be reduced. If Rybelsus is not reimbursed as an add-on treatment for patients with type 2 diabetes, there are several other alternative treatments available for these patients.
2016 ◽
Vol 30
(2)
◽
pp. 238-244
◽
2012 ◽
Vol 14
(8)
◽
pp. 762-767
◽